AUTHOR CORRECTION to: “Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer” (ERJ Open Res 2022; 8: 00239-2022)

Rolof G.P. Gijtenbeek; Vincent van der Noort; Joachim G. J. V. Aerts; Jeske A. Staal-Van Den Brekel; Egbert F. Smit; Frans H. Krouwels; Frank A. Wilschut; T. Jeroen N. Hiltermann; Wim Timens; Ed Schuuring; Joost D.J. Janssen; Martijn Goosens; Paul M. van den Berg; A. Joop de Langen; Jos A. Stigt; Ben E. E. M. van den Borne; Harry J. M.  Groen; Wouter H. van Geffen; Anthonie J. van der Wekken

doi:10.1183/23120541.50239-2022

AUTHOR CORRECTION to: “Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer” (ERJ Open Res 2022; 8: 00239-2022)

Rolof G.P. Gijtenbeek, Vincent van der Noort, Joachim G. J. V. Aerts, Jeske A. Staal-Van Den Brekel, Egbert F. Smit, Frans H. Krouwels, Frank A. Wilschut, T. Jeroen N. Hiltermann, Wim Timens, Ed Schuuring, Joost D.J. Janssen, Martijn Goosens, Paul M. van den Berg, A. Joop de Langen, Jos A. Stigt, Ben E. E. M. van den Borne, Harry J. M. Groen, Wouter H. van Geffen, Anthonie J. van der Wekken

Research output: Contribution to journal › Erratum

Original language	English
Article number	50239-2022
Journal	ERJ Open Research
Volume	10
Issue number	1
DOIs	https://doi.org/10.1183/23120541.50239-2022
Publication status	Published - 1-Jan-2024

Access to Document

10.1183/23120541.50239-2022Licence: CC BY-NC

Handle.net

Persistent link

Cite this

Gijtenbeek, R. G. P., van der Noort, V., Aerts, J. G. J. V., Staal-Van Den Brekel, J. A., Smit, E. F., Krouwels, F. H., Wilschut, F. A., Hiltermann, T. J. N., Timens, W., Schuuring, E., Janssen, J. D. J., Goosens, M., van den Berg, P. M., de Langen, A. J., Stigt, J. A., van den Borne, B. E. E. M., Groen, H. J. M., van Geffen, W. H., & van der Wekken, A. J. (2024). AUTHOR CORRECTION to: “Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer” (ERJ Open Res 2022; 8: 00239-2022). ERJ Open Research, 10(1), Article 50239-2022. https://doi.org/10.1183/23120541.50239-2022

@article{1a585e858fea46e99a568fbf38acc683,

title = "AUTHOR CORRECTION to: “Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer” (ERJ Open Res 2022; 8: 00239-2022)",

author = "Gijtenbeek, {Rolof G.P.} and {van der Noort}, Vincent and Aerts, {Joachim G. J. V.} and {Staal-Van Den Brekel}, {Jeske A.} and Smit, {Egbert F.} and Krouwels, {Frans H.} and Wilschut, {Frank A.} and Hiltermann, {T. Jeroen N.} and Wim Timens and Ed Schuuring and Janssen, {Joost D.J.} and Martijn Goosens and {van den Berg}, {Paul M.} and {de Langen}, {A. Joop} and Stigt, {Jos A.} and {van den Borne}, {Ben E. E. M.} and Groen, {Harry J. M.} and {van Geffen}, {Wouter H.} and {van der Wekken}, {Anthonie J.}",

year = "2024",

month = jan,

day = "1",

doi = "10.1183/23120541.50239-2022",

language = "English",

volume = "10",

journal = "ERJ Open Research",

issn = "2312-0541",

publisher = "European Respiratory Society",

number = "1",

}

Gijtenbeek, RGP, van der Noort, V, Aerts, JGJV, Staal-Van Den Brekel, JA, Smit, EF, Krouwels, FH, Wilschut, FA, Hiltermann, TJN , Timens, W , Schuuring, E, Janssen, JDJ, Goosens, M, van den Berg, PM, de Langen, AJ, Stigt, JA, van den Borne, BEEM, Groen, HJM, van Geffen, WH & van der Wekken, AJ 2024, 'AUTHOR CORRECTION to: “Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer” (ERJ Open Res 2022; 8: 00239-2022)', ERJ Open Research, vol. 10, no. 1, 50239-2022. https://doi.org/10.1183/23120541.50239-2022

AUTHOR CORRECTION to: “Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer” (ERJ Open Res 2022; 8: 00239-2022). / Gijtenbeek, Rolof G.P.; van der Noort, Vincent; Aerts, Joachim G. J. V. et al.
In: ERJ Open Research, Vol. 10, No. 1, 50239-2022, 01.01.2024.

Research output: Contribution to journal › Erratum

TY - JOUR

T1 - AUTHOR CORRECTION to

T2 - “Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer” (ERJ Open Res 2022; 8: 00239-2022)

AU - Gijtenbeek, Rolof G.P.

AU - van der Noort, Vincent

AU - Aerts, Joachim G. J. V.

AU - Staal-Van Den Brekel, Jeske A.

AU - Smit, Egbert F.

AU - Krouwels, Frans H.

AU - Wilschut, Frank A.

AU - Hiltermann, T. Jeroen N.

AU - Timens, Wim

AU - Schuuring, Ed

AU - Janssen, Joost D.J.

AU - Goosens, Martijn

AU - van den Berg, Paul M.

AU - de Langen, A. Joop

AU - Stigt, Jos A.

AU - van den Borne, Ben E. E. M.

AU - Groen, Harry J. M.

AU - van Geffen, Wouter H.

AU - van der Wekken, Anthonie J.

PY - 2024/1/1

Y1 - 2024/1/1

UR - http://www.scopus.com/inward/record.url?scp=85194262441&partnerID=8YFLogxK

U2 - 10.1183/23120541.50239-2022

DO - 10.1183/23120541.50239-2022

M3 - Erratum

AN - SCOPUS:85194262441

SN - 2312-0541

VL - 10

JO - ERJ Open Research

JF - ERJ Open Research

IS - 1

M1 - 50239-2022

ER -

Gijtenbeek RGP, van der Noort V, Aerts JGJV, Staal-Van Den Brekel JA, Smit EF, Krouwels FH et al. AUTHOR CORRECTION to: “Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer” (ERJ Open Res 2022; 8: 00239-2022). ERJ Open Research. 2024 Jan 1;10(1):50239-2022. doi: 10.1183/23120541.50239-2022

AUTHOR CORRECTION to: “Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer” (ERJ Open Res 2022; 8: 00239-2022)

Access to Document

Handle.net

Other files and links

Research output

Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer

Cite this